Endocrine Society Concerned Over Scaling Back ACA Contraception Coverage

The Endocrine Society expressed concerns Friday with the presidential administration’s new rules that would scale back the Affordable Care Act’s contraception coverage mandate.

The Society called for future health reform efforts to include continued access to no-cost hormonal contraception in a position statement issued last month.

The rules, which took effect Friday, allow companies to stop covering contraceptive services for their workers if they have religious or moral objections. The move will reduce some women’s ability to access birth control at no cost.

No-cost hormonal contraceptive services allow a woman to effectively plan if and when she becomes pregnant. This has a positive impact on families’ socioeconomic status and health. The resulting reduction in unplanned pregnancies also has a positive impact on healthcare costs.

Hormonal contraception’s health benefits extend beyond family planning. Endocrinologists frequently prescribe hormonal contraception to treat a variety of conditions, such as polycystic ovary syndrome (PCOS). Many birth control pill users use this contraceptive method to treat excessive menstrual bleeding, menstrual pain and acne. Hormonal contraception also can reduce a woman’s risk of developing ovarian and endometrial cancer.

By allowing employers to revert to pre-ACA cost-sharing requirements, the rules will increase the number of women who are unable to afford contraception.

You may also like

  • Holly A. Ingraham, PhD, Receives FASEB Excellence in Science Lifetime Achievement Award

    Endocrine Society member Holly A. Ingraham, PhD, is the recipient of the FASEB Excellence in Science Lifetime Achievement Award. On April 8, the organization announced the winners of its 2024 Excellence in Science Awards, which highlight outstanding achievements by women in biological sciences who demonstrate not only excellence and innovation in their research fields, but…

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

Find more in